- Home
- ORIS vs VYNE Comparison
ORIS vs VYNE Comparison
Compare ORIS & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIS
- VYNE
- Stock Information
- Founded
- ORIS 2014
- VYNE 2003
- Country
- ORIS China
- VYNE United States
- Employees
- ORIS N/A
- VYNE N/A
- Industry
- ORIS Farming/Seeds/Milling
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- ORIS Consumer Staples
- VYNE Health Care
- Exchange
- ORIS Nasdaq
- VYNE Nasdaq
- Market Cap
- ORIS 30.4M
- VYNE 35.7M
- IPO Year
- ORIS 2024
- VYNE 2018
- Fundamental
- Price
- ORIS $1.12
- VYNE $2.74
- Analyst Decision
- ORIS
- VYNE Strong Buy
- Analyst Count
- ORIS 0
- VYNE 2
- Target Price
- ORIS N/A
- VYNE $6.88
- AVG Volume (30 Days)
- ORIS 208.4K
- VYNE 86.1K
- Earning Date
- ORIS 02-21-2025
- VYNE 03-07-2025
- Dividend Yield
- ORIS N/A
- VYNE N/A
- EPS Growth
- ORIS N/A
- VYNE N/A
- EPS
- ORIS 0.43
- VYNE N/A
- Revenue
- ORIS $16,745,999.00
- VYNE $493,000.00
- Revenue This Year
- ORIS N/A
- VYNE $28.30
- Revenue Next Year
- ORIS N/A
- VYNE N/A
- P/E Ratio
- ORIS $2.60
- VYNE N/A
- Revenue Growth
- ORIS N/A
- VYNE 39.27
- 52 Week Low
- ORIS $0.94
- VYNE $1.57
- 52 Week High
- ORIS $56.01
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- ORIS N/A
- VYNE 56.12
- Support Level
- ORIS N/A
- VYNE $2.39
- Resistance Level
- ORIS N/A
- VYNE $2.65
- Average True Range (ATR)
- ORIS 0.00
- VYNE 0.20
- MACD
- ORIS 0.00
- VYNE 0.05
- Stochastic Oscillator
- ORIS 0.00
- VYNE 71.01
About ORIS Oriental Rise Holdings Limited Ordinary Shares
Oriental Rise Holdings Ltd is a company who is an integrated supplier of tea products in Mainland China. Their major tea products include primarily-processed tea consisting of white tea and black tea, and refined white tea and black tea. Its business operations are vertically integrated, covering cultivation, processing of tea leaves and the sale of tea products to tea business operators (such as wholesale distributors) and end-user retail customers in Mainland China.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.